Diagnostic de l’amplification du gène HER2 dans les cancers du sein
Authors:
- J. CouturierJCJ. Couturier
- M.-C. MathieuMMM.-C. Mathieu
- A. ValentAVA. Valent
- A. BernheimABA. Bernheim
- 1 September 2008
- journal article
- abstracts
- Published by Elsevier in Pathologie Biologie
- Vol. 56 (6) , 375-379
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast CancerJournal of Clinical Oncology, 2007
- Correction for chromosome-17 is critical for the determination of true Her-2/neu gene amplification status in breast cancerMolecular Cancer Therapeutics, 2006
- Gene amplification in cancerTrends in Genetics, 2006
- Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast CancerNew England Journal of Medicine, 2005
- The S-phase fraction of the aneuploid cell subpopulation is the biologically relevant one in aneuploid breast cancersBreast Cancer Research and Treatment, 2005
- Interlaboratory Comparison ofHER-2Oncogene Amplification as Detected by Chromogenic and Fluorescencein situHybridizationClinical Cancer Research, 2004
- HER-2 Testing in Breast Cancer Using Immunohistochemical Analysis and Fluorescence In Situ HybridizationAmerican Journal of Clinical Pathology, 2004
- Evaluating HER2 amplification and overexpression in breast cancerThe Journal of Pathology, 2001
- Strong Correlation between Results of Fluorescent In Situ Hybridization and Immunohistochemistry for the Assessment of the ERBB2 (HER-2/neu) Gene Status in Breast CarcinomaLaboratory Investigation, 2000
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neuOncogeneScience, 1987